| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.99▼ | 1.02▼ | 1.04▼ | 1.11▼ | 1.04▼ |
| MA10 | 1.03▼ | 1.06▼ | 1.08▼ | 1.03▼ | 1.15▼ |
| MA20 | 1.08▼ | 1.12▼ | 1.12▼ | 1.04▼ | 1.22▼ |
| MA50 | 1.13▼ | 1.09▼ | 1.06▼ | 1.17▼ | 1.37▼ |
| MA100 | 1.09▼ | 1.08▼ | 1.11▼ | 1.25▼ | 1.50▼ |
| MA200 | 1.12▼ | 1.19▼ | 1.18▼ | 1.39▼ | 2.56▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.011▼ | -0.021▼ | -0.022▼ | 0.013▲ | -0.026▼ |
| RSI | 22.776▼ | 28.155▼ | 31.892▼ | 42.266▼ | 38.565▼ |
| STOCH | 5.794▼ | 4.338▼ | 4.233▼ | 60.866 | 15.952▼ |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -76.129▼ | -86.981▼ |
| CCI | -130.119▼ | -164.665▼ | -186.559▼ | -26.497 | -80.557 |
|
Wednesday, October 21, 2026 01:13 AM
Merck secures expanded EU approval for KEYTRUDA plus Padcev in muscle-invasive bladder cancer after Phase 3 data showed improved survival outcomes.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/10/26 | 1.075 | 1.075 | 0.9725 | 0.9725 | 95,489 |
| 22/10/26 | 1.17 | 1.17 | 1.07 | 1.07 | 91,457 |
| 21/10/26 | 1.16 | 1.2675 | 1.13 | 1.13 | 149,935 |
| 20/10/26 | 1.19 | 1.24 | 1.11 | 1.16 | 209,417 |
| 19/10/26 | 1.085 | 1.20 | 1.05 | 1.20 | 574,637 |
| 16/10/26 | 1.02 | 1.20 | 1.00 | 1.04 | 1,129,711 |
| 15/10/26 | 0.96 | 0.96 | 0.88 | 0.92 | 120,200 |
| 14/10/26 | 0.92 | 0.95 | 0.89 | 0.89 | 65,800 |
| 13/10/26 | 1.03 | 1.03 | 0.91 | 0.9249 | 175,201 |
| 12/10/26 | 0.98 | 1.03 | 0.98 | 1.01 | 107,800 |
|
|
||||
|
|
||||
|
|